This bill makes Medicare cover treatments for dialysis-related amyloidosis, a serious condition that develops in people who have been on dialysis for many years. Dialysis-related amyloidosis happens when abnormal proteins build up in the body and damage bones, joints, and other tissues, causing pain and disability in long-term dialysis patients.

Right now, Medicare doesn't specifically cover treatments for this condition. This bill changes that by adding dialysis-related amyloidosis treatments to the list of services Medicare will pay for. The bill defines these treatments as any FDA-approved medication or procedure given in a dialysis facility, plus any necessary supplies or services that go along with the treatment.

The key financial part is that Medicare will pay 100 percent of the reasonable charges for these treatments separately, rather than bundling them into the regular dialysis payment. This means dialysis centers won't have to absorb the cost of these treatments into their existing dialysis fees. The changes take effect immediately once the bill becomes law, so Medicare beneficiaries who receive dialysis and develop this complication would gain access to covered treatment options that weren't previously available to them.